Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

New medicines could eliminate uterine fibroid surgeries

May 4, 2017 By Danielle Kirsh

uterine-fibroids-2

[Image from the U.S. Department of Health and Human Services]

Decision Resources Group, a healthcare research and data company, suggests that the launch of new medicines could provide a long-term management alternative to uterine fibroids surgeries over the next 10 years.

Effective medical alternatives to surgical procedures will include novel selective progesterone receptor modulators (SPRMs) including Allergan and Gedeon Richter’s ulipristal, Bayer’s vilaprisan, and Repros’s Proellex – and gonadotropin-releasing hormone (Gn-RH) antagonists including AbbVie’s elagolix, Myovant’s relugolix and ObsEva’s OBE2109. Hysterectomies and myomectomies are the current procedures for long-term management of uterine fibroids.

Uterine fibroids are muscular tumors that grow in the wall of the uterus, according to the Office on Women’s Health, part of the U.S. Department of Health and Human Services. Fibroids are usually non-cancerous but are still hard to live with. They can grow in varying sizes, from apple seed sized to grapefruit sized.

Approximately 20 to 80% of women get uterine fibroids by the time they’re 50 years old. It is most common in women who are in their 40s and 50s. The cause of fibroids is unknown, but hormones and genetics play a factor.

Fibroids are diagnosed with an ultrasound, magnetic resonance imaging, X-rays, CT scans, hysterosalpingogram or sonohysterogram.

Gn-RH medications are typically delivered by injection, nasal spray or implants. They are designed to shrink fibroids and are sometimes used before surgery to help make fibroid removal easier.

Decision Resources Group also forecasts that the drug treatment rate will increase gradually as pharmacological treatment options for long-term management of uterine fibroids increase. Low-cost hormonal contraceptives, tranexamic acid and NSAIDs will continue to be the main drug therapies for controlling heavy bleeding that comes with uterine fibroids.

With the increase of drug therapies, Decision Resources Group predicts that the number of surgical procedures will decrease.

“Medical alternatives, for instance, SPRMs and the second-generation, orally administered Gn-RH antagonists, which effectively control heavy menstrual bleeding and can bypass the need for surgical procedure, will be preferred by patients who opt to stay on drug therapy until menopause,” said Decision Resource Group analyst Jing Wu in a press release. “The adoption of these novel therapies will be key in driving significant expansion of the uterine fibroids therapeutic market within the 2016–2026 forecast period.”

[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]

You may also like:


  • This uterine fibroid treatment is underused despite being cost-effective

Related Articles Read More >

A portrait of Dr. Kevin Chung, chief medical officer at SeaStar Medical
Device developer SeaStar Medical hires chief medical officer
A portrait of AcuityMD co-founder and CEO Michael Monovoukas
Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
Harvard Science and Engineering Complex SEC SEAS Harvard John A. Paulson School of Engineering and Applied Sciences
Here’s where Harvard’s engineering dean sees medtech research going
An illustration of a cloud-shaped room filled with medical devices
The cloud is transforming medtech: Amazon, Microsoft, Google, J&J, Philips and GE Healthcare leaders explain

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech